1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals
Nippon Kayaku Co., Ltd.

Nippon Kayaku Co., Ltd.

NPKYY
Nippon Kayaku Co., Ltd.US flagOther OTC
13.16
USD
- -
- -
1.95BMarket Cap
Nippon Kayaku Co., Ltd.
NPKYY
(Other OTC)

Recent

price

13.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
777.11
820.95
811.52
- -
883.22
893.22
905.42
918.19
969.58
997.08
1,014.69
1,015.17
1,093.9
1,183.07
1,216.73
1,362.48
626.91
Revenue per Share
54.39
71.7
62.89
- -
92.25
86.38
96.08
90.22
89.45
85.77
74.25
73.62
101.7
89.36
24.8
107.17
-11.94
Basic EPS, GAAP
73.84
58.05
56.84
- -
65.31
25.12
26.49
95.52
41.45
61.98
62.74
63.73
80.94
42.06
43.53
-33.53
- -
Free Cash Flow per Basic Share
19.93
19.93
19.93
- -
19.96
27.44
25.11
30.15
32.42
29.93
30.02
29.92
30.01
45.03
47.36
45.27
- -
Dividend per Share
570.56
622.6
665.77
- -
790.33
852.01
928.84
1,024.57
1,082.35
1,138.15
1,153.48
1,209.29
1,245.98
1,299.53
1,291.23
1,332.26
1,305.85
Book Value per Share
680.81
728.48
769.73
- -
965.31
1,087.31
1,102.08
1,174.27
1,253.45
1,302.66
1,197.33
1,296.51
1,413.73
1,481.88
1,609.02
1,618.86
1,569.98
Tangible Book Value per Share
181
181
181
181
181
181
180
173
173
173
173
171
169
168
166
163
166
Basic Weighted Avg Shares
141,029
148,897
147,119
- -
160,068
161,857
162,936
159,112
167,882
172,640
175,133
173,384
184,805
198,380
201,791
222,584
103,883
Sales/Revenue/Turnover
11.34
13.99
13.19
- -
15.05
13.78
13.33
12.35
13.47
11.55
9.98
8.76
11.39
10.84
3.64
9.17
2.47
Operating Margin (%)
10,028
9,029
9,931
- -
10,435
10,743
11,238
11,343
11,673
11,969
12,584
13,473
14,099
14,240
14,402
14,077
- -
Depreciation Expense
9,871
13,004
11,401
- -
16,718
15,653
17,291
15,635
15,488
14,851
12,815
12,574
17,181
14,984
4,113
17,508
-1,979
Net Income, GAAP
7.35
34.63
33.09
- -
28.98
29.89
27.27
26.88
26.52
26.32
29.01
28.15
27.24
28.27
42
20.12
56.43
Effective Tax Rate (%)
7
8.73
7.75
- -
10.44
9.67
10.61
9.83
9.23
8.6
7.32
7.25
9.3
7.55
2.04
7.87
-1.91
Profit Margin (%)
74,625
82,239
82,491
- -
100,572
102,367
111,430
112,281
115,068
120,546
114,302
119,361
130,083
146,988
143,331
151,188
132,519
Working Capital
11,672
11,143
6,934
- -
13,717
9,518
12,460
8,201
7,577
8,778
18,182
15,770
9,474
16,200
18,000
34,884
15,400
LT Debt
127,829
135,796
144,017
- -
177,933
199,678
200,490
205,863
220,616
229,042
210,018
228,272
246,424
255,024
270,547
268,518
264,200
Total Equity
9.5
8.69
8.07
- -
16.85
7.45
7.19
6.45
7.24
6.09
5.16
4.51
5.95
5.68
1.47
5.29
- -
Return on Invested Capital (%)
7.26
8.86
7.46
- -
17.66
8.17
8.62
7.46
7.12
6.46
5.76
5.63
7.55
6.43
1.7
6.95
1.69
Return on Capital (%)
9.83
12.01
9.76
- -
23.34
10.52
10.76
9.07
8.49
7.73
6.47
6.2
8.24
7
1.9
8.11
-0.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,450
- -
13,300
LT Borrowings
18,000
- -
15,400
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
166
- -
164
Market Capitalization
- -
- -
214,130

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
203,146
- -
195,196
Cash, Cash Equivalents & STI
66,177
- -
53,786
Accounts Receivable, Net
60,267
- -
59,840
Inventories
67,008
- -
71,886
Total Current Liabilities
59,815
- -
62,677
Payables & Accruals
- -
- -
- -
ST Debt
13,450
- -
13,300
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.12%
5.09%
-0.75%
Free Cash Flow
5%
-39.16%
-175.87%
Net Income, GAAP
25.72%
55.02%
325.67%
Sales/Revenue/Turnover
3.31%
4.99%
10.3%
Total Cash Common Dividend
5.12%
8.99%
-5.86%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,584
49,324
51,845
52,038
201,791
2025
- -
- -
- -
- -
222,584
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.05
- -
- -
- -
24.8
2025
- -
- -
- -
- -
107.17
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
47.36
2025
- -
- -
- -
- -
45.27
2026
- -
- -
- -
- -
- -
Similar Companies
China Sanjiang Fine Chemicals Company Limited (2198.HK)
Anhui Huaertai Chemical Co., Ltd. (001217.SZ)
Guangdong Orient Zirconic Ind Sci & Tech Co.,Ltd (002167.SZ)
SGL Carbon SE (SGL.DE)
Cydsa, S.A.B. de C.V. (CDSAF)
AlumiFuel Power Corporation (AFPW)
Business
Nippon Kayaku Co., Ltd. Nippon Kayaku Co., Ltd. develops, manufactures and markets functional chemicals, pharmaceuticals, safety systems and agrochemicals across Japan, Asia, Europe and other international markets; founded in 1916 and headquartered in Tokyo, Japan. The Functional Chemicals segment provides epoxy resins and UV-curable resins for semiconductors and displays, photoresists and insulating materials for microelectromechanical systems, inkjet colorants, textile and paper dyes, catalysts for acrylic acid production, polarizing films, liquid crystal components and x-ray analysis parts; the Pharmaceuticals segment offers anti-cancer agents including ROS1 inhibitors, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drug intermediates and diabetes markers like GlycoMark; the Safety Systems segment supplies airbag inflators for driver, passenger, side, curtain and knee applications, micro gas generators for seatbelt pretensioners and squibs; the Agrochemicals segment delivers insecticides, herbicides, soil fumigants and sanitary insecticides. In August 2025, the company executed a shareholders agreement with Formiica Pharmaceuticals Pte. Ltd. and CBC Co., Ltd. to establish a Singapore-based joint venture for in-licensing and sublicensing pharmaceuticals into Asia including Japan and Oceania, granting Nippon Kayaku preferential rights for Japanese development and sales; in November 2025, it launched IBTROZI Capsules 200mg, an oncology drug for ROS1 fusion-positive non-small cell lung cancer exclusively licensed from Nuvation Bio Inc., following national health insurance listing; additionally in November 2024, it initiated a share buyback of up to 6.5 million shares for 7.0 billion yen to boost capital efficiency.